Limitations of the present study included the comparator choice of erlotinib (a tyrosine kinase inhibitor of EGFR) in this population for which available clinical data have been limited and inconsistent (7, 27–31).Initially, erlotinib was indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least 1 prior chemotherapy regimen (11); and National Comprehensive Cancer Network guidelines supported erlotinib as a subsequent second- or third-line treatment option. Here, EGFR is linked to non-small cell lung carcinoma.